We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' p... Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. Show more
– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session – – Additional Presentations to Highlight Quality of Life Data from...
CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
– Topline Data Readout from the Phase 3 ENERGIZE-T Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia now expected in Q2 2024 – – Announced Positive Results from...
CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
– Report Highlights Company’s Focus on Red Blood Cell Health; Diversity, Equity & Inclusion; and Strong Corporate Governance – – Aligns with the Sustainability Accounting Standards Board...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.4 | 4.25015179114 | 32.94 | 35.33 | 32.45 | 493892 | 34.11665488 | CS |
4 | 5.07 | 17.3214895798 | 29.27 | 35.48 | 28.71 | 694237 | 32.6968061 | CS |
12 | 4.47 | 14.9648476733 | 29.87 | 35.48 | 27.14 | 725683 | 31.41683411 | CS |
26 | 11.87 | 52.8259902092 | 22.47 | 35.48 | 20.96 | 714954 | 27.33507431 | CS |
52 | 8.64 | 33.6186770428 | 25.7 | 35.48 | 19.795 | 590905 | 26.32596653 | CS |
156 | -20.62 | -37.5181950509 | 54.96 | 62.155 | 16.75 | 598576 | 30.89749967 | CS |
260 | -14.81 | -30.1322482197 | 49.15 | 62.155 | 16.75 | 640891 | 36.60990968 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions